The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis.

OBJECTIVE: To estimate the pooled prevalence of cancer in patients with multiple sclerosis (MS) cases who were under treatment with rituximab. METHODS: We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (("CD20 Antibody" AND Rituximab) OR "Rituximab CD20 Antibody" OR Mabthera OR "IDEC-C2B8 Antibody" OR "IDEC C2B8 Antibody" OR IDEC-C2B8 OR "IDEC C2B8" OR GP2013 OR Rituxan OR rituximab) AND ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR "disseminated sclerosis" OR "multiple sclerosis" OR "acute fulminating"). RESULTS: The literature search revealed 3577 articles, after deleting duplicates 2066 remained. For the meta-analysis, 22 studies were included. Totally, 15599 patients were enrolled while 133 cancers were detected. The pooled prevalence of cancer in MS patients under treatment with rituximab is 1in 100,000 (I2 = 99.9%, p < 0.001). CONCLUSION: The results of this systematic review and meta-analysis show that the pooled prevalence of cancer in MS patients who received rituximab is 1 in 100,000 cases.

The prevalence of sexual dysfunction and erectile dysfunction in men with multiple sclerosis: A systematic review and meta-analysis.

BACKGROUND: The prevalence of sexual dysfunction (SD) in men with multiple sclerosis (MS) is reported variously in different studies. The most common form of SD in these patients is erectile dysfunction (ED). The goal of this systematic review and meta-analysis is to determine the pooled prevalence of SD and ED in men suffering from MS. METHODS: We searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, and gray literature (references of references, and congress abstracts) up to 14th November 2020. RESULTS: We found 3163 studies by primary search, 2246 were included after deletion of duplicates. Finally, 29 studies were included for meta-analysis. A total of 3349 patients were evaluated. The pooled prevalence of SD was 66% (95% CI: 64%-69%). The pooled prevalence of erectile dysfunction was 49% (95% CI: 47%-50%). CONCLUSION: Sexual dysfunction is a prevalent complication of MS in male patients which should be considered by clinicians.

Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis.

OBJECTIVE: This study aimed to compute the pooled prevalence of diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis. METHOD: A systematic literature review was performed in PubMed, Scopus, Web of Science, Embase and Google Scholar. The cross-sectional studies that reported the frequency of diabetes mellitus in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis were included. RESULTS: Eighteen eligible studies with a total number of 3718 patients were included in the current study. The pooled prevalence of diabetes in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis was 89 per cent and with new-onset diabetes was 32 per cent. The pooled prevalence of steroid use was high (79 per cent) too. The all-cause mortality rate was 24 per cent. CONCLUSION: Diabetes mellitus was the most frequent underlying condition in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis. The second most frequent underlying condition was steroid use during coronavirus disease 2019 infection. The appropriate control of hyperglycaemia and rational prescription of steroids during the treatment of coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis is recommended.

Sexual function in women with primary and secondary infertility in comparison with controls.

Infertility is a distressing health condition that has diverse effects on couples' lives. One of the most affected aspects of life in infertile women is sexual function, which is a key factor in physical and marital health. The goal of this study was to evaluate sexual function according to the type of infertility in comparison with controls. In this study, 191 women with primary infertility and 129 with secondary infertility along with 87 age-matched healthy controls were enrolled. They were asked to fill a valid and reliable FSFI (Female Sexual Function Index). Age, partner age and duration of marriage were significantly different between the primary and secondary infertility groups. The score of each FSFI domain was significantly higher in the control group, and the only significant difference between primary and secondary infertility groups was in the desire domain. Multiple linear regression analysis between the total FSFI score as a dependent variable and age, partner age, Body Mass Index and marriage duration as independent variables showed that age is a dependent predictor of FSFI in the primary group. We found significant negative correlation between total FSFI score and age, partner age and marriage duration (r1=-0.21 and P<0.001, r2=-0.14 and P=0.01, r3=-0.19 and P<0.001). Sexual dysfunction is high in all infertile women, and women with secondary infertility suffer more from impaired sexual function compared with those with primary infertility.